Crown Bioscience Announces Four New Preclinical NASH Models In Development

Ads

You May Also Like

Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

HEIDELBERG, Germany, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage ...

Resverlogix Announces Participation in Upcoming Conferences

CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") ...

Rexahn Pharmaceuticals Announces Leadership Transition

Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, Md., Nov. 14, 2018 (GLOBE ...